價(jià)格 | ¥1410 | ¥8310 | ¥5540 |
包裝 | 1mg | 10mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-30 |
中文名稱(chēng):化合物 (S)-SLV 319 | 英文名稱(chēng):(S)-SLV 319 |
CAS:464213-10-3 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
產(chǎn)品類(lèi)別: 抑制劑 | |
貨號(hào): T21914 |
名稱(chēng) | (S)-SLV 319 |
描述 | Ibipinabant (SLV319) is a potent, selective, and orally active antagonist of the cannabinoid CB1 receptor, demonstrating a K i of 7.8 nM and exhibiting over 1000-fold selectivity for CB1 compared to CB2 (K i =7943 nM). It is utilized in obesity and diabetes research [1] [2] [3]. |
體外活性 | SLV319 displaces the specific CP-55940 (CB agonist) binding in CHO cells stably transfected with human CB1 receptor, with a K i of 7.8 nM [1]. WIN-55212 (CB1 agonist)-induced arachidonic acid release in CHO cells is antagonized by SLV319 concentration-dependently with a pA2 of 9.9 [1]. |
體內(nèi)活性 | SLV319 (3 mg/kg/day; p.o. for 28 d) reduces the food intake, body weight, and hormonal/metabolic abnormalities in diet-induced obesity (DIO) mice [2]. SLV319 (3 mg/kg/day, p.o. for 28 d) reverses the HFD-induced increase in adipose tissue leptin mRNA [2]. SLV319 (3-10 mg/kg; daily oral gavage for 56 d) shows weight loss-independent antidiabetic effects and attenuates β-cell loss in a rat model of progressive β-cell dysfunction [3]. SLV319 (oral administration) antagonizes CB agonist (CP55940) induced hypotension in rats and hypothermia in mice, with an ED 50 of 5.5 and 3 mg/kg, respectively [1]. Animal Model: Six-week-old male C57Bl/6J mice received a diet containing 60% of calories as fat, resulting in body weights >42 g in 12-14 weeks [2] Dosage: 3 mg/kg/day Administration: P.o. for 28 days Result: Caused reductions in food intake, body weight and adiposity in DIO mice. |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
關(guān)鍵字 | SLV-319 | SLV 319 | (S) SLV 319 | (S)SLV 319 | SLV319 |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP2年
|
德陽(yáng)思諾生物科技有限公司
|
2024-10-21 | |
詢(xún)價(jià) |
VIP1年
|
廣州佳途科技股份有限公司
|
2024-10-23 | |
詢(xún)價(jià) |
VIP1年
|
青島愷潤(rùn)生物醫(yī)藥科技有限公司
|
2024-11-02 | |
詢(xún)價(jià) |
VIP6年
|
鎮(zhèn)江中智化學(xué)科技有限公司
|
2024-10-14 |